A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH
Part of paid clinical trials in Gardena, California.
- Sponsor
- Cascade Pharmaceuticals, Inc
- Study ID
- NCT05591079
- Phase
- PHASE2
- Status
- Completed
Conditions
- Nonalcoholic Steatohepatitis (NASH)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- CS0159 (Linafexor) — DRUGOral QD
Study Details
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of CS0159 in subjects with Non-Alcoholic Steatohepatitis (NASH)
Key Dates
- First listed
- Oct 24, 2022
- Start date
- Feb 10, 2023
- Status verified
- Jul 2023
- Primary completion
- Nov 9, 2023
- Completion
- Nov 9, 2023
Study Design
- Enrollment
- 99 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 1.4mg CS0159One tablet daily for 12 weeks
- Experimental: 2mg CS0159One tablet daily for 12 weeks
- Placebo Comparator: PLACEBOOne tablet daily for 12 weeks
Primary Outcome Measure
MRI-PDFF [ Time Frame: Week 12 ]
Locations (17)
Find similar trials in Gardena, CA
By research site
National Research Institute - Gardena· Gardena, CAVelocity Clinical Research, Huntington Park· Huntington Park, CAVelocity Clinical Research - Panorama City· Panorama City, CAVelocity Clinical Research - Santa Ana· Santa Ana, CAOcala GI Research· Lady Lake, FLFlorida Research Institute· Lakewood, FL
Related Studies
- Evaluating the Pharmacokinetics and Safety of MiricorilantPHASE1 · Recruiting · Corcept Therapeutics · San Antonio, Texas